Adiponectin and thiazolidinedione targets CRTC2 to regulate hepatic gluconeogenesis

34Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

During fasting periods, hepatic glucose production is enhanced by glucagon to provide fuels for other organs. This process is mediated via cAMP-dependent induction of the CREB regulated transcriptional coactivator (CRTC) 2, a critical transcriptional activator for hepatic gluconeogenesis. We have previously shown that CRTC2 activity is regulated by AMP activated protein kinase (AMPK) family members. Here we show that adiponectin and thiazolidinedione directly regulate AMPK to modulate CRTC2 activity in hepatocytes. Adiponectin or thiazolidinedione lowered glucose production from primary hepatocytes. Treatment of both reagents reduced gluconeogenic gene expression as well as cAMP-mediated induction of CRE reporter, suggesting that these reagents directly affect CREB/CRTC2- dependent transcription. Furthermore, adiponectin or thiazolidinedione mediated repression of CRE activity is largely blunted by co-expression of phosphorylation defective mutant CRTC2, underscoring the importance of serine 171 residue of this factor. Taken together, we propose that adiponectin and thiazolidinedione promote the modulation of AMPK-dependent CRTC2 activity to influence hepatic gluconeogenesis.

Cite

CITATION STYLE

APA

Yoon, Y. S., Ryu, D., Lee, M. W., Hong, S., & Koo, S. H. (2009). Adiponectin and thiazolidinedione targets CRTC2 to regulate hepatic gluconeogenesis. Experimental and Molecular Medicine, 41(8), 577–583. https://doi.org/10.3858/emm.2009.41.8.063

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free